Vivimed Labs Limited, together with its subsidiaries, manufactures and sells active pharmaceutical ingredients (APIs), finished dosage formulations, specialty chemicals, and retail branded formulations in India. It operates through two segments, Speciality Chemicals Business and Pharma Business. The company provides APIs and intermediates to generic and ethical companies; and branded formulations in therapeutic segments, such as ophthalmic, nutraceuticals, dermatology, and pain, as well as contract manufacturing of capsules and tablets, syrups and liquids, and nasal sprays and ointments. It also exports its products. The company was incorporated in 1988 and is based in Hyderabad, India.
| Current Price | ₹6.21 |
|---|---|
| Market Cap | ₹55 Cr |
| Sector | Health Care > Pharmaceuticals, Biotechnology and Life Sciences > Pharmaceuticals |
| Sub-Industry | Pharmaceuticals > Pharmaceutical Contract Manufacturing Services |
| P/E Ratio | -0.3 |
| 52-Week Range | ₹4.75 – ₹26.60 |
| Beta (1Y) | -1.3 |
| Dividend Yield | 0.00% |
| Revenue | ₹12 Cr |
|---|---|
| Net Profit | ₹-146 Cr |
| EPS (Basic) | ₹-17.74 |
| Basis | consolidated |
Figures in ₹ crore, parsed from the company's exchange filing (XBRL).
Vivimed Labs Ltd. is trading at ₹6.21, with a market capitalisation of ₹55 Cr.
Vivimed Labs Ltd. operates in the Health Care > Pharmaceuticals, Biotechnology and Life Sciences > Pharmaceuticals space (Pharmaceuticals > Pharmaceutical Contract Manufacturing Services).
Vivimed Labs Ltd. has a P/E of -0.3.
In Q4 FY26, Vivimed Labs Ltd. reported revenue of ₹12 Cr and net profit of ₹-146 Cr, with basic EPS of ₹-17.74 (consolidated, parsed from the company's exchange filing).